fda drug safety communication semaglutide naion 2025 GLP-1 medicine and non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives Semaglutide and the Risk of

Key monitoring parameters include: Blood glucose levels : Continue regular self-monitoring of blood glucose as advised by your diabetes team

In the study, participants followed a diet and exercise program, which is a requirement when taking semaglutide for weight loss

Someone taking 1.7 mg weekly who cannot tolerate the post-injection nausea might switch to 0.85 mg on Monday and 0.85 mg on Thursday

It found a substantially increased risk of deep vein thrombosis (DVT) for patients taking semaglutide drugs to treat type 2 diabetes

Further competition comes from tirzepatide, approved by the FDA in 2022 and now sold under the Mounjaro/Zepbound brand name.